Skip to main
AGMB

AGMB Stock Forecast & Price Target

AGMB Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AgomAb Therapeutics is paving the way for novel disease-modifying therapies for chronic fibrotic indications with high unmet medical need, making it an attractive investment for those seeking to capitalize on the rising demand for effective treatments in this space. While there are challenges within the development of antifibrotic treatments, the company's pipeline, particularly Ontunisertib, has shown promising results and is backed by strong financials. With the company's focus on addressing limitations associated with prior treatment approaches and expanding into other indications like Crohn's disease and liver disease, the future looks bright for AgomAb Therapeutics and its potential impact on improving patient outcomes.

Bears say

AgomAb Therapeutics is a promising clinical-stage company targeting fibrotic diseases with a well-validated anti-fibrotic target and innovative pharmacokinetic strategy to avoid side effects. With a first-mover advantage in the market and multiple drugs in development—including Ontunisertib and AGMB-447—the company has potential for high sales and is forecasting high revenue. Further progress and potential partnerships in 2026 are expected to drive growth and reinforce its position in this growing market.

AGMB has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AgomAb Therapeutics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AgomAb Therapeutics SA (AGMB) Forecast

Analysts have given AGMB a Buy based on their latest research and market trends.

According to 5 analysts, AGMB has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AgomAb Therapeutics SA (AGMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.